Genetically modified mouse

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Retrieved on: 
Friday, July 23, 2021

Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (GLP) toxicology study using a transgenic mouse model of Alzheimers disease.

Key Points: 
  • Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (GLP) toxicology study using a transgenic mouse model of Alzheimers disease.
  • The positive GLP toxicology results represent a key milestone for Alzamend as we continue to advance our proprietary pipeline.
  • We believe AL002 could potentially reverse the effects of Alzheimers disease.
  • A five-dose GLP study with AL002-sensitized cells was completed using a transgenic (or genetically modified) mouse model of Alzheimers disease to investigate the tolerability of AL002.

Global Humanized Mice Model Market to 2025 by Service, Type, Immune Checkpoints, Application, End-user, and Region

Retrieved on: 
Thursday, January 21, 2021

The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.

Key Points: 
  • The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.
  • In addition to this, increasing investments for research in laboratories and institutes is positively impacting the growth of the market.
  • The Global Humanized Mice Model Market is segmented based on service, type, immune checkpoints, application, end-user, and region.
  • Based on type, the market is fragmented into cell line transplantation model, patient derived xenografts, genetically engineered mouse model and others.

Taconic Biosciences launches critical model for COVID-19 research

Retrieved on: 
Monday, October 26, 2020

RENSSELAER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research.

Key Points: 
  • RENSSELAER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research.
  • Transgenic mice expressing the human ACE2 receptor overcome this challenge and thus are critical for COVID-19 research.
  • Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services.
  • Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.

Global Humanized Mice Model (Cell-line transplantation model, Patient based xenografts, Genetically Engineered Mice, Others) Market, Competition, Forecast & Opportunities, 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 16, 2020

The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.

Key Points: 
  • The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.
  • In addition to this, increasing investments for research in laboratories and institutes is positively impacting the growth of the market.
  • The Global Humanized Mice Model Market is segmented based on service, type, immune checkpoints, application, end-user, and region.
  • Based on type, the market is fragmented into cell line transplantation model, patient derived xenografts, genetically engineered mouse model and others.